Subtype
Esophageal and Gastroesophageal Junction Carcinoma
CI-CAN-00002608Explore in graph →
460 active trials11 approved drugs34 evidence items
- NCIt
- C203673
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002608Explore in graph →
Clinical trials
1,309 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (120)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.(FORTITUDE-102) | terminated | Phase 3 | 515 | AmgenINDUSTRY | 29 | Sep 10, 2026 | clinicaltrials |
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). | terminated | Phase 3 | 863 | Merck Sharp & Dohme LLCINDUSTRY |
| 25 |
| Aug 21, 2026 |
| clinicaltrials |
| NCT06549413 | 18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer | terminated | — | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 227 | Novartis PharmaceuticalsINDUSTRY | 9 | Jul 9, 2026 | clinicaltrials |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | terminated | Phase 1 | 47 | BeOne MedicinesINDUSTRY | 5 | Jul 8, 2026 | clinicaltrials |
| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | terminated | Phase 1 | 57 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT07040059 | A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | terminated | Phase 1 / Phase 2 | 2 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05567835 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer(TOGAR) | terminated | Phase 2 | 3 | Baylor College of MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 30 | Novartis PharmaceuticalsINDUSTRY | 9 | Feb 17, 2026 | clinicaltrials |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 1 | 42 | Prelude TherapeuticsINDUSTRY | 6 | Feb 2, 2026 | clinicaltrials |
| NCT03042169 | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer(SURGIGAST) | terminated | Phase 3 | 6 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab(NIRADO) | terminated | Phase 2 | 51 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | terminated | Phase 1 | 50 | Blueprint Medicines CorporationINDUSTRY | 3 | Nov 28, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT04363801 | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer(DisTinGuish) | terminated | Phase 2 | 247 | Leap Therapeutics, Inc.INDUSTRY | 3 | Oct 9, 2025 | clinicaltrials |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | terminated | Phase 1 | 122 | Novartis PharmaceuticalsINDUSTRY | 9 | Sep 30, 2025 | clinicaltrials |
| NCT03320629 | A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 7 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05834543 | Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 34 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05461794 | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 96 | BeiGeneINDUSTRY | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04727151 | TAC T-cells for the Treatment of HER2-positive Solid Tumors(TACTIC-2) | terminated | Phase 1 / Phase 2 | 28 | Triumvira Immunologics, Inc.INDUSTRY | 2 | Jun 8, 2025 | clinicaltrials |
| NCT05311176 | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)(nextHERIZON) | terminated | Phase 2 | 7 | Imugene LimitedINDUSTRY | 2 | May 11, 2025 | clinicaltrials |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | terminated | Phase 2 | 205 | Seagen Inc.INDUSTRY | 6 | Mar 10, 2025 | clinicaltrials |
| NCT04804696 | Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 10 | Peking UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT05229900 | A Study of SGN-ALPV in Advanced Solid Tumors | terminated | Phase 1 | 43 | Seagen Inc.INDUSTRY | 5 | Feb 10, 2025 | clinicaltrials |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | terminated | Phase 1 | 111 | Seagen Inc.INDUSTRY | 6 | Feb 7, 2025 | clinicaltrials |
| NCT02485834 | FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer | terminated | Phase 2 | 5 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04162665 | Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05555251 | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors(CONTRAST) | terminated | Phase 1 / Phase 2 | 18 | BioInvent International ABINDUSTRY | 3 | Dec 16, 2024 | clinicaltrials |
| NCT03366012 | Rapid Assessment of Esophageal Adenocarcinoma Risk Test(REACT) | terminated | N/A | 51 | Columbia UniversityOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | terminated | Phase 1 | 15 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB) | terminated | Phase 1 | 160 | Inhibrx Biosciences, IncINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | terminated | Phase 1 / Phase 2 | 13 | BioNTech SEINDUSTRY | 2 | Oct 2, 2024 | clinicaltrials |
| NCT05780736 | A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer(PROSPECT-ESO) | terminated | — | 33 | Bristol-Myers SquibbINDUSTRY | 2 | Sep 25, 2024 | clinicaltrials |
| NCT06206278 | Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma | terminated | Phase 2 | 6 | LianBio LLCINDUSTRY | 1 | Aug 14, 2024 | clinicaltrials |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma(FIDES-03) | terminated | Phase 1 / Phase 2 | 47 | Basilea PharmaceuticaINDUSTRY | 15 | Apr 4, 2024 | clinicaltrials |
| NCT05687617 | Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma. | terminated | Phase 2 | 11 | Laval UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT01307956 | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer | terminated | Phase 2 | 11 | University of NebraskaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT04977401 | EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection(EPSILON) | terminated | N/A | 32 | Erasme University HospitalOTHER | 3 | Oct 23, 2023 | clinicaltrials |
| NCT03722108 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas(REGIRI) | terminated | Phase 1 / Phase 2 | 89 | UNICANCEROTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT02530437 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | terminated | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | May 31, 2023 | clinicaltrials |
Data updated 19 days agoSource updated Sep 10, 2026source: clinicaltrials